# A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC

> **NCT05144529** · PHASE2 · TERMINATED · sponsor: **Eziafa Oduah, MD, PhD, MPH** · enrollment: 19 (actual)

## Conditions studied

- Lung Cancer Metastatic

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Evolocumab

## Key facts

- **NCT ID:** NCT05144529
- **Lead sponsor:** Eziafa Oduah, MD, PhD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-22
- **Primary completion:** 2024-09-27
- **Final completion:** 2024-09-27
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Slow enrollment.
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05144529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05144529, "A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05144529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*